Colesevelam - Cosmo Pharmaceuticals
Alternative Names: CB-01-33; Colesevelam hydrochloride-MMXLatest Information Update: 16 Sep 2025
At a glance
- Originator Cosmo Pharmaceuticals
- Class Amines; Antihyperglycaemics; Antihyperlipidaemics; Digestion aids; Polymers
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Primary bile acid malabsorption
Most Recent Events
- 16 Sep 2025 Cosmo Technologies plans a phase II trial in Primary bile acid malabsorption in Demark, Belgium, Italy, Romania, Spain in June 2025 (CTIS2024-511993-55-00)
- 26 Jul 2023 Cosmo Pharmaceuticals plans a phase I trial for Primary bile acid malabsorption in H2 2023
- 23 Mar 2023 Cosmo Pharmaceuticals completes IP protection completion for Colesevelam